ClinicalTrials.gov
ClinicalTrials.gov Menu

Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ) (CHEMPAQ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01138618
Recruitment Status : Completed
First Posted : June 7, 2010
Last Update Posted : November 7, 2011
Sponsor:
Collaborator:
Aalborg Psychiatric Hospital
Information provided by (Responsible Party):
University of Aarhus

Study Description
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Clozapine remain the drug of choice for treatment resistant schizophrenia and up to 60% of patients not responding to other antipsychotics will respond to clozapine. However, the use of clozapine is restricted due to the risk of agranulocytosis and consequently the need for mandatory hematological monitoring. CHEMPAQ XBC is a point-of-care device that can be used in patients home and analyze WBC and granulocytes by a single capillary blood drop. This study aims to investigate whether this new procedure increases the acceptability of clozapine

Condition or disease Intervention/treatment
Schizophrenia Device: Venous blod sample Device: CHEMPAQ

Study Design
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Actual Enrollment : 85 participants
Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ)
Study Start Date : April 2010
Actual Primary Completion Date : December 2010
Actual Study Completion Date : May 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia
Drug Information available for: Clozapine
U.S. FDA Resources

Groups and Cohorts
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
CHEMPAQ-venous-CHEMPAQ-venous
The two arms only differ in order of kind of blood samples.
 Device: Venous blod sample
Regular venous blood sample withdrawn from the laboratory
Device: CHEMPAQ
Capillary blood sample analyzed by CHEMPAQ
Venous-CHEMPAQ-Venous-CHEMPAQ
The two arms only differ in order of kind of blood samples.
 Device: Venous blod sample
Regular venous blood sample withdrawn from the laboratory
Device: CHEMPAQ
Capillary blood sample analyzed by CHEMPAQ


Outcome Measures
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Pain sensation [ Time Frame: Monthly for four months ]
    Pain sensation was measured using a visual analog scale (VAS)


Secondary Outcome Measures :
  1. The benefits of CHEMPAQ [ Time Frame: Monthly for four months ]
    Caregivers and patients were asked about the benefits of using CHEMPAQ for hematological clozapine monitoring.


Eligibility Criteria
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients treated with clozapine
Criteria

Inclusion Criteria:

  • Treated with clozapine
  • Compliant with blood monitoring
  • Willing to give informed consent

Exclusion Criteria:

  • Prior case of agranulocytosis
Contacts and Locations
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01138618


Locations
Denmark
Aalborg Psychiatric Hospital
Aalborg, Denmark, 9000
Psychiatric Center Aarhus
Aarhus, Denmark, 8240
Psychiatric Center Copenhagen
Copenhagen, Denmark
Psychiatric Centre Esbjerg
Esbjerg, Denmark
Psychiatric Center Roskilde
Greve, Denmark, 2670
Psychiatric Center Odense
Odense, Denmark, 5000
Sponsors and Collaborators
University of Aarhus
Aalborg Psychiatric Hospital
Investigators
Principal Investigator: Jimmi Nielsen, MD Aalborg Psychiatric Hospital, Aarhus University Hospital
More Information
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications:

Responsible Party: University of Aarhus
ClinicalTrials.gov Identifier: NCT01138618     History of Changes
Other Study ID Numbers: 1.5 - 01 MARCH2010
First Posted: June 7, 2010    Key Record Dates
Last Update Posted: November 7, 2011
Last Verified: November 2011

Keywords provided by University of Aarhus:
Clozapine
hematological monitoring
CHEMPAQ
Granulocytes
WBC

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Clozapine
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
 Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
GABA Antagonists
GABA Agents